Work to develop vaccines and treatments for COVID-19 is continuing around the world. Companies are joining forces to boost their efforts, and progress is being made on the research front. Meanwhile, the economic impacts of the pandemic have been widespread, with big pharma companies seeing double-digit declines in their valuations over the course of the first quarter of 2020, albeit with a few exceptions.
Coronavirus Update: A Key Vaccine Partnership, Promising Treatments, And A Rocky First Quarter
A new COVID-19 vaccine dream team, updated trial results on remdesivir, and a rough first quarter for big pharma stocks. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, these three topics are among a selection of brief insights we’re bringing you on biopharma commercial activities.